Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) has been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $58.00.
A number of equities research analysts recently commented on PCRX shares. Piper Sandler lowered their price objective on shares of Pacira BioSciences from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Thursday, August 3rd. HC Wainwright reduced their target price on Pacira BioSciences from $68.00 to $63.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Truist Financial lowered their target price on Pacira BioSciences from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, August 3rd. StockNews.com initiated coverage on Pacira BioSciences in a report on Thursday. They issued a “buy” rating for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $68.00 price objective on shares of Pacira BioSciences in a research note on Tuesday.
Read Our Latest Research Report on Pacira BioSciences
Hedge Funds Weigh In On Pacira BioSciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. Engineers Gate Manager LP acquired a new position in shares of Pacira BioSciences in the 4th quarter valued at about $2,012,000. New York Life Investment Management LLC acquired a new stake in shares of Pacira BioSciences in the first quarter worth $473,000. State of New Jersey Common Pension Fund D raised its stake in shares of Pacira BioSciences by 15.4% in the 1st quarter. State of New Jersey Common Pension Fund D now owns 54,882 shares of the company’s stock valued at $2,240,000 after acquiring an additional 7,306 shares during the period. Federated Hermes Inc. raised its stake in shares of Pacira BioSciences by 332,486.7% in the 1st quarter. Federated Hermes Inc. now owns 149,664 shares of the company’s stock valued at $6,108,000 after acquiring an additional 149,619 shares during the period. Finally, Inspire Investing LLC lifted its holdings in shares of Pacira BioSciences by 9.8% during the 1st quarter. Inspire Investing LLC now owns 6,674 shares of the company’s stock valued at $272,000 after acquiring an additional 595 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.
Pacira BioSciences Price Performance
PCRX stock opened at $29.80 on Monday. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -186.24 and a beta of 0.73. The company has a current ratio of 3.94, a quick ratio of 3.10 and a debt-to-equity ratio of 0.66. The firm has a 50 day moving average of $34.88 and a 200-day moving average of $38.46. Pacira BioSciences has a 12-month low of $28.45 and a 12-month high of $58.09.
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last posted its earnings results on Wednesday, August 2nd. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.02. Pacira BioSciences had a positive return on equity of 11.56% and a negative net margin of 0.68%. The company had revenue of $169.47 million for the quarter, compared to the consensus estimate of $175.64 million. As a group, equities analysts expect that Pacira BioSciences will post 2.37 EPS for the current fiscal year.
Pacira BioSciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.
See Also
Receive News & Ratings for Pacira BioSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pacira BioSciences and related companies with MarketBeat.com’s FREE daily email newsletter.